|
This is Ipsen’s second acquisition this week, following its blockbuster Kartos buyout on 29 June.
|
 |
|
The approval is supported by data from the STEER, Phase IIIb STRENGTH and Phase I/II STRONG studies.
|
|
|
The deal could include further milestone payments, potentially bringing the total value to approximately $600m.
|
|
|
The ROTOR platform will initially be developed and validated using rotavirus vaccine datasets.
|
|
|
The industry looks set to continue a preference for European outsourcing facilities as national tax systems exert influence.
|
|
|
Combining whole genome data with AimedBio’s drug development approach is expected to speed up clinical development.
|
|
